Original Articles

Comparison of the Toric Implantable Collamer Lens and Bioptics for Myopic Astigmatism

Sung-Ho Choi, MD; Myoung-Ok Lee, MD; Eui-Sang Chung, MD, PhD; Tae-Young Chung, MD, PhD

  • Journal of Refractive Surgery
  • February 2011 - Volume 27 · Issue 2: 91-97
  • DOI: 10.3928/1081597X-20100414-01
Rights and Permissions

Abstract

Purpose:

To compare results between toric implantable collamer lens (TICL) implantation and bioptics (ICL and excimer laser ablation) for the correction of myopic astigmatism.

Methods:

A retrospective evaluation was performed in 29 eyes (20 patients) with TICL implantation and 26 eyes (17 patients) treated with bioptics. For eyes treated with bioptics, corneal ablation was performed at 1.5 to 5 months (mean 2.56 months) after ICL implantation by laser epithelial keratomileusis in 17 eyes, LASIK in 8 eyes, and photorefractive keratectomy in 1 eye. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity, refraction, adverse events, safety, and efficacy were assessed preoperatively and 1, 6, and 12 months postoperatively.

Results:

At 1 month postoperatively, UDVA in the TICL group was significantly higher than in the bioptics group (P=.02). However, the difference in UDVA at 12 months was not significant. At 12 months, mean spherical equivalent refraction was 0.33±0.21 diopters (D) in the TICL group and 0.29±0.41 D in the bioptics group (P=.07). Mean astigmatic error was higher in the TICL group (−0.42±0.32 D) than in the bioptics group (−0.32±0.38 D) (P=.10). In the bioptics group, the mean refractive cylinder at 12 months decreased from that reported at 6 months because of retreatment performed in two eyes. Safety and efficacy were not statistically different between groups. One eye with a TICL was treated to correct TICL decentration. Two crystalline lens opacities were observed after bioptics.

Conclusions:

This study demonstrates that TICL implantation provides reliable visual outcomes similar to bioptics. The advantages of TICL implantation are a more stable visual outcome and the elimination of laser treatments and their inherent risks.

AUTHORS

From the Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs (A084721) and Samsung Biomedical Research Institute Grant, #SBRI C-B0-317-1, Republic of Korea.

The authors have no proprietary or financial interest in the materials presented herein.

Correspondence: Tae-Young Chung, MD, PhD, Dept of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, #50 Irwon-dong, Gangnam-gu, Seoul 130-710, Korea. Tel: 82 2 3410 3563; Fax: 82 2 3410 0074; E-mail: tychung@skku.edu

Received: July 21, 2009
Accepted: March 02, 2010
Posted Online: April 15, 2010

doi: 10.3928/1081597X-20100414-01

Healio is intended for health care provider use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will Healio be used for medical advice to patients.

[X]